作者: Roberto Pellicciari , Emidio Camaioni , Gabriele Costantino
DOI: 10.1016/S0079-6468(04)42003-7
关键词:
摘要: Publisher Summary The recent past has seen a remarkable interest in the understanding of pathophysiology poly(ADP-ribosyl)ation vivo . Novel and promising therapeutic opportunities, particularly, for treatment ischaemia related central nervous system diseases, are becoming apparent poly(ADP-ribose)polymerase (PARP) modulators. Rational medicinal chemistry approaches successfully complementing more direct, genetic approach elucidating role PARP family pathological conditions, availability new tools, hopefully subtype selective, will provide basis thorough pharmacological characterization en route toward clinically useful agents.